Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Size Matters: Novartis Says Vaccines are for Big Manufacturers, Marketers

This article was originally published in RPM Report

Executive Summary

The vaccine business is made-to-order for Big Pharma. That's how Novartis is portraying the business to the financial community-a good growing environment if you can afford to reach scale. One of Novartis' partners in development, the Austrian firm Intercell, has also become a hot performer based on its strong piipeline of projects. Maybe there is room for both large and small.

You may also be interested in...



Novartis Bets Big on Meningitis:Wall Street Awaits Blockbuster Vaccine Franchise

Two years after shaking up the vaccine field with its big entry-acquisition of Chiron, Novartis AG has identified a make-or-break pair of projects in the meningitis area. The meningitis vaccines will determine whether the Novartis bet on vaccines will turn into a smart long-term diversification or a low-return move into an unfamiliar and unfriendly segment of health care.

Novartis Bets Big on Meningitis:Wall Street Awaits Blockbuster Vaccine Franchise

Two years after shaking up the vaccine field with its big entry-acquisition of Chiron, Novartis AG has identified a make-or-break pair of projects in the meningitis area. The meningitis vaccines will determine whether the Novartis bet on vaccines will turn into a smart long-term diversification or a low-return move into an unfamiliar and unfriendly segment of health care.

Novartis/Chiron: Validating the Value of Vaccine R&D

Nothing solidifies the emergence of a hot investment sector like a big investment of cash, and Novartis AG provided that with its two-stage $5.7 billion close out of the remaining shares of Chiron Corp. that it did not already own (W#200510159). Novartis bought $300 million worth of Chiron's stock in December 2005 and then closed out the deal with $5.4 billion in April 2006.

Topics

Related Companies

UsernamePublicRestriction

Register

PS080454

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel